Skip to main content

PAPEL DE IDE EN EL ACLARAMIENTO Y LA ACCION DE LA INSULINA EN EL HIGADO

PID2019-110496RB-C22

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Targeting Insulin-Degrading Enzyme in Insulin Clearance

  • Leissring, Malcolm A.
  • González-Casimiro, Carlos M.
  • Merino, Beatriz
  • Suire, Caitlin N.
  • Perdomo, Germán
© 2021 by the authors., Hepatic insulin clearance, a physiological process that in response to nutritional cues clears ~50–80% of circulating insulin, is emerging as an important factor in our understanding of the pathogenesis of type 2 diabetes mellitus (T2DM). Insulin-degrading enzyme (IDE) is a highly conserved Zn2+-metalloprotease that degrades insulin and several other intermediate-size peptides. Both, insulin clearance and IDE activity are reduced in diabetic patients, albeit the cause-effect relationship in humans remains unproven. Because historically IDE has been proposed as the main enzyme involved in insulin degradation, efforts in the development of IDE inhibitors as therapeutics in diabetic patients has attracted attention during the last decades. In this review, we retrace the path from Mirsky’s seminal discovery of IDE to the present, highlighting the pros and cons of the development of IDE inhibitors as a pharmacological approach to treating diabetic patients., This research was funded by the Ministerio de Economía, Industria y Competitividad, grant number SAF2016-77871-C2-2-R to G.P.; Ministerio de Ciencia e Innovación PID2019-110496RB-C22 to G.P.; European Foundation for the Study of Diabetes (European Diabetes Research Programme on New Targets for Type 2 Diabetes supported by MSD-2017) to G.P.; European Foundation for the Study of Diabetes (EFSD) -Novo Nordisk to B.M.; and the US National Institutes of Health (GM115617) to M.A.L. The project leading to these results has received funding from “La Caixa” Foundation, under agreement LCF/PR/PR18/51130007 to G.P. C.M.G.-C. was supported by a fellowship from the Junta de Castilla y León and the European Social Fund (ORDER EDU/574/2018). B.M. was supported by a “Rising Star” fellowship (EFSD-Novo Nordisk).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Primary Cilia in Pancreatic ß- and ¿-Cells: Time to Revisit the Role of Insulin-Degrading Enzyme

  • Pablos, Marta
  • Casanueva-Álvarez, Elena
  • González-Casimiro, Carlos M.
  • Merino, Beatriz
  • Perdomo, Germán
  • Cózar-Castellano, Irene
The primary cilium is a narrow organelle located at the surface of the cell in contact with the extracellular environment. Once underappreciated, now is thought to efficiently sense external environmental cues and mediate cell-to-cell communication, because many receptors, ion channels, and signaling molecules are highly or differentially expressed in primary cilium. Rare genetic disorders that affect cilia integrity and function, such as Bardet-Biedl syndrome and Alström syndrome, have awoken interest in studying the biology of cilium. In this review, we discuss recent evidence suggesting emerging roles of primary cilium and cilia-mediated signaling pathways in the regulation of pancreatic β- and α-cell functions, and its implications in regulating glucose homeostasis, The project leading to this Review has received funding from “La Caixa” Foundation, under agreement LCF/PR/PR18/51130007 to GP; Grants PID2019-110496RB-C21 and PID2019-110496RB-C22 funded by MCIN/AEI/10.13039/501100011033 to IC-C and GP, respectively; European Foundation for the Study of Diabetes Rising Star Fellowship to BM supported by EFSD-Novo Nordisk; This research was funded by the Programa Estratégico Instituto de Biología y Genética Molecular (IBGM), Junta de Castilla y León (CCVC8485). CG-C and EC-Á were supported by a fellowship from the Junta de Castilla y León and the European Social Fund (ORDER EDU/574/2018 and ORDER EDU/556/2019, respectively).